Journal article icon

Journal article

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial

Abstract:

Statins are the accepted standard for lowering low-density lipoprotein-cholesterol (LDLC). However, 5%-10% of statin-treated patients report intolerance, mostly due to musclerelated adverse effects. There are challenges to objective identification of patients with statin intolerance. Evolocumab is a monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), resulting in marked LDL-C reduction. We report the design of Goal Achievement after Utilizing an anti-PCSK9 An...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1002/clc.22518

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Nuffield Department of Population Health, Clinical Trial Service Unit
Nissen, SE More by this author
Dent-Acosta, RE More by this author
Rosenson, RS More by this author
Expand authors...
Publisher:
Wiley Publisher's website
Journal:
Clinical Cardiology Journal website
Publication date:
2016-03-05
DOI:
URN:
uuid:e23b5e3f-db8d-480b-9893-c494bac0bd43
Source identifiers:
608947
Local pid:
pubs:608947

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP